NeoTherapeutics and GPC Biotech Sign Agreement To Co-Develop Phase 3 Oral Anti-Cancer Drug NeoTherapeutics to receive licensing fees, milestone payments and royalties; GPC Biotech to fully fund development and commercialization costs Tuesday October 1, 2:00 am ET IRVINE, Calif., Oct.
NeoTherapeutics Provides Update on Nasdaq Listing Status Monday September 30, 7:52 pm ET IRVINE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOTD) has filed an application for listing on the Nasdaq small cap exchange. The Company has been notified by Nasdaq that it
NeoTherapeutics Regains Compliance with NASDAQ Minimum Bid Requirement Thursday September 26, 11:54 am ET IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOTD) announced today that NASDAQ has notified the Company that it has regained compliance with NASDAQ's
NeoTherapeutics' Stockholders Approve Reverse Stock Split and Proposal for New Financings Trading on post-split basis to commence September 6, 2002 Thursday September 5, 2:41 pm ET IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/-- NeoTherapeutics Inc. (Nasdaq: NEOT), announced today that its
NeoTherapeutics Announces Organizational Changes Designed to Bring On-Going Monthly Expenses Below $500,000 Changes solidify strategic commitment to anti-cancer drug development and out-licensing of neurology products IRVINE, Calif., Aug. 22 /PRNewswire-FirstCall/-- NeoTherapeutics, Inc.
NeoTherapeutics Announces New Financial Leadership IRVINE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT ) announced today the retirement of Samuel Gulko, Senior Vice President, Finance; Chief Financial Officer; Secretary; and, Treasurer. Mr.
NeoTherapeutics Announces Major Strategic Restructuring Company to focus resources on development of phase 3 anti-cancer drug and licensing out anti-psychotic and attention deficit drugs IRVINE, Calif., Aug. 20 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc.
NeoTherapeutics Names Dr. Rajesh Shrotriya Chairman and Chief Executive Officer New CEO to assume duties immediately IRVINE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- The Board of Directors of NeoTherapeutics, Inc. (Nasdaq: NEOT) announced today the appointment of Rajesh C. Shrotriya, M.D.
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.